Publications by authors named "Lars Tanum"

Claim this Profile
C
Chronic Pain and Posttraumatic Stress Among Patients in Substance Use Treatment: Protocol for NOR-APT, a Longitudinal Cohort Study.
Ingeborg Skjærvø, Anne Marciuch, Linn Wergeland Digranes, Lena M Follerås, Jon Mordal, Lars Tanum

JMIR Res Protoc· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reward Sensitivity in Patients Receiving Opioid Agonist and Antagonist Treatment for Opioid Use Disorder: An Observational Study.
Martin Trøstheim, Mads Lund Pedersen, Siri Leknes, Lennja Majid Hama, Mathias Nikolai Roland, Lars Tanum

Biol Psychiatry Cogn Neurosci Neuroimaging· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Measuring Personal Recovery in a Sample of People with Opioid Use Disorder: Psychometric Properties of the Norwegian Version of the Questionnaire about the Process of Recovery.
Anne Marciuch, Regina Skar-Fröding, Kristin Klemmetsby Solli, Lars Tanum, Bente Weimand

Eur Addict Res· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in quality of life during 52 weeks of extended-release naltrexone treatment, subsequent by a 1-year post-treatment period.
Christina L Redondo, Bente Weimand, Jūratė Šaltytė Benth, John-Kåre Vederhus, Jon Mordal, Lars Tanum

Drug Alcohol Depend· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain intensity in patients using extended-release naltrexone or opioid agonists and its effect on extended-release naltrexone treatment outcomes.
Farid Juya, Kristin K Solli, Line Holtan, Ann-Christin Sannes, Bente Weimand, Lars Tanum

Am J Addict· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Analysis of Lysophosphatidic Acid Levels in Fibromyalgia and Other Painful Conditions in Female Patients.
Joana Menezes, Jenny E Jakobsson, Alex Bersellini Farinotti, Emerson Krock, Matthew A Hunt, Lars Tanum

Eur J Pain· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High induction rate onto extended-release naltrexone for people with opioid use disorder: experiences from a Norwegian naturalistic study.
Jon Mordal, Farid Juya, Line Holtan, John-Kåre Vederhus, Arild Opheim, Lars Tanum

Addict Sci Clin Pract· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in mental health during long-term treatment with extended-release naltrexone: A 3-year clinical study of opioid dependent individuals.
Kristin Klemmetsby Solli, Jūratė Šaltytė Benth, Linn Camilla Wergeland Digranes, Line Holtan, Nikolaj Kunoe, Lars Tanum

Contemp Clin Trials· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients with Opioid Use Disorder Choosing Treatment with Extended-Release Naltrexone: A 6-Month Naturalistic Study.
Ida Halvorsen Brenna, Karin Merethe Waleur, Jūratė Šaltytė Benth, Kristin K Solli, Jon Mordal, Lars Tanum

Eur Addict Res· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pain Intensity in Patients with Opioid Use Disorder on Extended-Release Naltrexone or Opioid Agonists; The Role of COMT rs4680 and OPRM1 rs1799971: An Exploratory Study.
Farid Juya, Ann Christin Sannes, Kristin Klemmetsby Solli, Bente Weimand, Johannes Gjerstad, Lars Tanum

J Pain Res· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial.
Håvard Midgard, Kristian Braathen Malme, Charlotte Meinich Pihl, Riikka Mari Berg-Pedersen, Lars Tanum

Clin Infect Dis· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of relapse to non-opioid addictive substances among opioid dependent patients treated with an opioid receptor antagonist or a partial agonist: A randomized clinical trial.
Arild Opheim, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, Pia S Kloster, Lars Thore Fadnes, Lars Tanum

Contemp Clin Trials· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone.
Anne Marciuch, Bente Birkeland, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, Lars Tanum

Heliyon· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adverse childhood experiences and their association with substance use disorders in adulthood: A general population study (Young-HUNT).
Rosalie Broekhof, Hans M Nordahl, Lars Tanum, Sara G Selvik

Addict Behav Rep· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Impulsivity, Hyperactivity, and Inattention on Discontinuation Rate among Opioid-Dependent Patients Treated with Extended-Release Naltrexone.
Ann Tarja Karlsson, John-Kåre Vederhus, Thomas Clausen, Bente Weimand, Kristin Klemmetsby Solli, Lars Tanum

Int J Environ Res Public Health· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.
Anne Marciuch, Ida Halvorsen Brenna, Bente Weimand, Kristin Klemmetsby Solli, Lars Tanum

Addict Sci Clin Pract· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
'
'Not at all what I had expected': Discontinuing treatment with extended-release naltrexone (XR-NTX): A qualitative study.
Ida Halvorsen Brenna, Anne Marciuch, Bente Birkeland, Marius Veseth, Bente Røstad, Lars Tanum

J Subst Abuse Treat· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Life satisfaction among individuals with opioid use disorder receiving extended-release naltrexone: A 12-week randomized controlled trial and a 36-week follow-up.
Zhanna Gaulen, Jūratė Šaltytė Benth, Lars Thore Fadnes, Ida Halvorsen Brenna, Lars Tanum

J Subst Abuse Treat· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Predictive Value of Degree of Preference for Extended-Release Naltrexone for Treatment Adherence, Opioid Use, and Relapse.
Zhanna Gaulen, Ida Halvorsen Brenna, Lars Thore Fadnes, Jūratė Šaltytė Benth, Kristin K Solli, Lars Tanum

Eur Addict Res· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of Relapse Among Opioid-Dependent Patients Treated With Extended-Release Naltrexone or Buprenorphine-Naloxone: A Randomized Clinical Trial.
Arild Opheim, Zhanna Gaulen, Kristin Klemmetsby Solli, Zill-E-Huma Latif, Lars T Fadnes, Lars Tanum

Am J Addict· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Levels of Impulsivity, Hyperactivity, and Inattention and the Association with Mental Health and Substance Use Severity in Opioid-Dependent Patients Seeking Treatment with Extended-Release Naltrexone.
Ann Tarja Karlsson, John-Kåre Vederhus, Thomas Clausen, Bente Weimand, Kristin Klemmetsby Solli, Lars Tanum

J Clin Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic Pain Among Patients With an Opioid Use Disorder.
Zill-E Huma Latif, Ingeborg Skjaervø, Kristin K Solli, Lars Tanum

Am J Addict· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adapting treatment length to opioid-dependent individuals' needs and preferences: A 2-year follow-up to a 1-year study of extended-release naltrexone.
Kristin Klemmetsby Solli, Arild Opheim, Zill-E-Huma Latif, Peter Krajci, Jūratė Šaltytė Benth, Lars Tanum

Addiction· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Antipsychotic Medication Management Fidelity Scale: Psychometric properties.
Torleif Ruud, Karin Drivenes, Robert E Drake, Vegard Øksendal Haaland, Matthew Landers, Lars Tanum

Adm Policy Ment Health· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discrepancy in Ratings of Shared Decision Making Between Patients and Health Professionals: A Cross Sectional Study in Mental Health Care.
Karin Drivenes, Vegard Ø Haaland, Yina L Hauge, John-Kåre Vederhus, Audun C Irgens, Lars Tanum

Front Psychol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis